The Data Is Now Official

The full Phase 3 trial results for daraxonrasib were published in the New England Journal of Medicine on May 31, 2026, and simultaneously presented Sunday at the American Society for Clinical Oncology meeting in Chicago. A cancer breakthrough that survives both peer review and presentation to the field's leading specialists remains rare enough to note.

The Numbers, Straight

The trial enrolled 500 patients with metastatic pancreatic cancer whose disease had stopped responding to prior treatment. They were randomly assigned to either daraxonrasib or more chemotherapy.

Patients on daraxonrasib lived a median of 13.2 months. Patients on chemotherapy lived a median of 6.7 months. That's nearly double.

Patients on the pill also stayed on treatment longer, reported less pain, and rated their quality of life higher. Their tumors shrank. Many were still on the drug when researchers locked the data, suggesting the survival advantage could widen.

New Calls for a Standard-of-Care Shift

Top oncologists are calling for an immediate change in treatment protocol. Dr. Brian Wolpin of the Dana-Farber Cancer Institute presented the findings Sunday and said daraxonrasib should become "a new standard of care" for previously treated metastatic pancreatic cancer, according to NPR.

Wolpin also said researchers plan to explore the drug earlier in the disease — including testing whether tumor shrinkage could help more patients qualify for surgery. If tumors shrink enough to allow surgery, that would shift treatment possibilities for most pancreatic cancer patients diagnosed too late for the operating room.

The Emotional Weight in the Room

Dr. Rachna Shroff of the University of Arizona Cancer Center, who had no involvement in the study, told ASCO attendees Sunday that she "actually started crying" when she first saw the results, according to NPR. Having treated pancreatic cancer patients, Shroff understood the significance of seeing patients remain on an effective treatment.

Dr. Zev Wainberg of UCLA, who helped lead the study, said: "While not curing the cancer, it is a very large step forward."

What the British Press Got Right — and Overstated

Across the Atlantic, the UK press ran this story hard on Monday's front pages. The Mirror called it "game changing." The Daily Express reported that three quarters of UK adults diagnosed with pancreatic cancer currently die within one year, and half die within three months — providing context for the significance of these results.

The Express also noted that experts hope daraxonrasib's mechanism could eventually extend to other cancer types. The drug targets a mutated protein called KRAS that appears across multiple cancers. The trial data, however, covers pancreatic cancer patients specifically.

What Mainstream Coverage Is Leaving Out

Most coverage avoids the cost and access question. A drug this significant, targeting a protein involved in more than 90% of pancreatic cancer cases according to NPR, will command commercial pricing. The company behind daraxonrasib has NOT publicly announced pricing. The FDA's Fast Track designation accelerates review but does nothing to control patient costs.

Pancreatic cancer kills about 66,000 Americans per year according to prior research. It's predominantly diagnosed in people over 65 — those on Medicare and most exposed to drug pricing decisions. Insurance coverage and out-of-pocket costs remain unaddressed in medical press coverage.

Also: this drug targets second-line patients — people whose cancer already stopped responding to first treatment. Earlier-line trials are still ahead. That data does not yet exist.

What This Means for Regular People

If you or someone you know has been told their pancreatic cancer isn't responding to chemo, this drug exists and the data is real. Ask your oncologist specifically about daraxonrasib. It's FDA Fast Track. The trial data is published. The medical community is moving.

Median survival of 13.2 months is not a cure. It represents additional time — months for conversations, additional treatment options, time that many patients and families expected not to have.

For one of the deadliest cancers, a drug that nearly doubles survival and gets published in the New England Journal of Medicine in the week of its public presentation marks a significant moment. The next question is implementation—whether insurance and access systems keep pace with the science.